Qiufei Ma
Overview
Explore the profile of Qiufei Ma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ailawadhi S, Inocencio T, Mansfield C, Chintakayala P, Bussberg C, Chi L, et al.
Future Oncol
. 2025 Feb;
21(7):853-865.
PMID: 40012263
Aims: To quantify patient preferences for attributes of novel treatments for triple-class-exposed (TCE) relapsed and/or refractory multiple myeloma (RRMM). Methods: Using a discrete-choice experiment, we elicited preferences for 7 attributes:...
2.
Delea T, Ma Q, Kroog G, Ge W, Moynahan A, Sabater Anaya N, et al.
Oncol Ther
. 2024 Aug;
12(3):565-583.
PMID: 39097860
Introduction: Treatment of multiple myeloma (MM) has been transformed by novel therapies, including CD38 monoclonal antibodies (mAbs), immunomodulatory drugs (IMiDs), and proteasome inhibitors (PIs), resulting in increasing numbers of patients...
3.
Johnson P, Bailey A, Ma Q, Milloy N, Butcher J, Sanderson I, et al.
Front Oncol
. 2024 Jul;
14:1402992.
PMID: 38978741
Background: Real-world health-related quality of life (HRQoL) data in patients with diffuse large B-cell lymphoma (DLBCL) are scarce. This study is to compare patient-reported outcomes in patients with DLBCL across...
4.
Johnson P, Bailey A, Ma Q, Milloy N, Biondi E, Quek R, et al.
Adv Ther
. 2024 Jul;
41(8):3342-3361.
PMID: 38976122
Introduction: Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin's lymphoma (NHL), characterized by a long natural course of remissions/relapses. We aimed to evaluate real-world quality of life (QoL) in...
5.
Zhai Y, Pang C, Sun S, Ma Q, Han L, Gu Y, et al.
Infect Drug Resist
. 2021 Dec;
14:5175-5181.
PMID: 34908851
Purpose: Systematic review of infection associated with ophthalmology, and to summarize the clinical characteristics of keratitis after refractive surgery. Methods: Case report and literature review. Results: We report an 18-year-old...
6.
Li Z, Liu R, Ma Q, Yu X, Xu Z, Guo Z, et al.
Ocul Surf
. 2021 Nov;
23:216-218.
PMID: 34728380
No abstract available.
7.
Verneris M, Ma Q, Zhang J, Keating A, Tiwari R, Li J, et al.
Blood Adv
. 2021 Oct;
5(23):5387-5395.
PMID: 34597381
In the absence of head-to-head trials, an indirect-treatment comparison can estimate the treatment effect of tisagenlecleucel in comparison with blinatumomab on rates of complete remission (CR) and overall survival (OS)...
8.
Eichten C, Ma Q, Delea T, Hagiwara M, Ramos R, Iorga S, et al.
Pharmacoeconomics
. 2021 Jul;
39(10):1163-1183.
PMID: 34273085
Background And Objective: The objective of this study was to estimate the lifetime costs of patients receiving treatment for follicular lymphoma (FL) in the United States. Methods: A Markov model...
9.
Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, et al.
Transplant Cell Ther
. 2021 Apr;
27(6):506.e1-506.e10.
PMID: 33823168
There are limited treatment options and substantial unmet needs for adult patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL) in Japan. In 2019, tisagenlecleucel, a CD19-directed...
10.
Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, et al.
Transplant Cell Ther
. 2021 Mar;
27(3):241.e1-241.e11.
PMID: 33781519
Until recently, treatment options were relatively limited for children and young adults with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). Tisagenlecleucel is a chimeric antigen receptor T cell (CAR-T)...